This rule addresses key areas of Medicaid drug reimbursement and changes made to the Medicaid Drug Rebate Program by the Affordable Care Act (ACA). The rule will be published in the February 1st edition of the Federal Register and also provides for an additional comment period on the definition and identification of line extension drugs. Comments are due March 31, 2016. Rule is effective on April 1, 2016.
The amendment is to be effective no later than April 1, 2017 and must comply with three separate requirements.